Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7769
IPSCIO Record ID: 1395
(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.
â€œHumanized Antibody(ies)â€ means the humanized form of the Murine Antibody.
â€œLicensed Product(s)â€ means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.
â€œMurine Antibody(ies)â€ means, subject to Section 2.01(b), the murine monoclonal antibody designated as â€œPRO 140â€ directed against the Target Antigen.
IPSCIO Record ID: 3851
An employee of the Licensor, is the inventor who has submitted the following disclosures, a portion of which constitute the Invention (i) UA1524, Therapeutic Monoclonal IgA Antibodies to Cryptosporidium Antigens of 500KDa and Less Than 1,000KDa; (ii) UA1525, Anti-GP23 Antigen Monoclonal IgA Antibodies for Treatment of Cryptosporidiosis, G9H4 and H8H2 and (iii) UA1526, Monoclonal IgA Antibody 1B8 Directed to Cryptosporidium 200KDa Antigen.
IPSCIO Record ID: 280827
Licensor shall transfer to Licensee the XenoMouse Animals and other materials.
The executed option will provide exclusivity.
The materials include Forty ( 40) XenoMouseâ„¢ animals; 2 mg human anti- KLH antibody (generated in XenoMouse); Immunization protocol; Fusion protocol; and, ELISA protocol for screening.
The research collaboration agreement is to generate fully human antibodies to an antigen target in the field of inflammation.
IPSCIO Record ID: 6777
IPSCIO Record ID: 2968
The Licensee purchased rights to the first antibody on June 6, 2007 and exercised its option for the purchase of rights to the second antibody on February 7, 2008.
IPSCIO Record ID: 29291